Seeking Alpha

Healthcare Specialist

View as an RSS Feed
View Healthcare Specialist's Comments BY TICKER:
Latest  |  Highest rated
  • Inovio's Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals [View article]
    I keep telling people about Inovios DNA vaccination potential, and here's proof to go with it!
    Jun 14, 2013. 07:33 AM | Likes Like |Link to Comment
  • Will Influenza A H7N9 Generate Opportunities For Pharma? [View article]
    Excellent article, I've been watching Greffex and Nvax very closely over the last week!
    May 23, 2013. 01:32 AM | Likes Like |Link to Comment
  • Pricing A Highly Probable Takeover Of MannKind [View article]
    I bought in at $1.98, and sold out of my shares today at $6.47. I'll call it profit taking but I think it's oversold at this point and due for a pullback.

    Don't get me wrong, I love the company and the product, things just seem a bit out of hand with it at the moment.
    May 22, 2013. 11:06 AM | Likes Like |Link to Comment
  • A Tale Of Three Pharmaceuticals: Getting Exciting In 2013 [View article]
    Excellent article, very well thought out and written.

    I have written on Inovio several times in the past, and currently have a good sized stake in them as I honestly believe in a lot of their technology. From a medical viewpoint their vaccination technique and equipment is extremely safe and sound, and has extreme potential. Plus their staff is overqualified to say the least!
    Apr 29, 2013. 02:00 PM | 5 Likes Like |Link to Comment
  • Delcath: A Cancer Treatment Biotech With Good Short And Long-Term Potential [View article]
    I'm curious as to why you feel the FDA doesn't want this device approved, is there any specific reason or issue with the technology?

    FDA aside, the potential global market that is already being successfully developed seems to be a safety net for investors. If it ultimately fails, it will undoubtedly reflect in the price, but will rebound quickly on the next global development.
    Apr 21, 2013. 06:31 AM | 2 Likes Like |Link to Comment
  • Merck's Promising Vaccine Empire [View article]
    Excellent article!

    Have you looked at INO at all? I wrote about them in a few of my past articles and I have a great feeling about the prospects of their DNA vaccines since most of their staff are Ex-Merck employees; most of which had a successful hand in vaccines including Gardasil.
    Apr 19, 2013. 12:30 PM | Likes Like |Link to Comment
  • Apple $395: Time To Give Up And Abandon Ship? [View article]
    Heck I invest in Biotech/Biopharms and I won't even touch Apple because its entire future is risky speculation. With the new advances in smartphone/tablet technology that comes out every day there is a significantly less chance that they'll make a comeback with a revolutionary product.
    Apr 19, 2013. 12:26 PM | 1 Like Like |Link to Comment
  • Inovio Pharmaceuticals (INO +0.4%) says Phase 1 studies of its SynCon universal H1N1 influenza vaccine generated protective antibody levels comparable to a current FDA-approved seasonal influenza vaccine against a currently circulating influenza strain. INO adds that this is the first demonstration of a SynCon influenza vaccine achieving a protective immune response rate comparable to a conventional seasonal vaccine for a circulating influenza strain. [View news story]
    Right after I mentioned them in my Influenza article yesterday!
    Apr 18, 2013. 02:33 PM | 1 Like Like |Link to Comment
  • 3 Microcap Biopharma Plays For The H7N9 Influenza Outbreak [View article]
    BLUE BELL, Pa., April 18, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO:$0.5675,$0.0235,4... today announced that it was presented Vaccine Industry Excellence (ViE) Awards for "Best Therapeutic Vaccine" and "Best Early Stage Biotech" at the World Vaccine Congress, which is being held this week in Washington, D.C. The ViE Awards recognize outstanding vaccine advancements and achievements of vaccine developers across the global industry as judged by a panel of global biotech industry stakeholders.

    The "Best Therapeutic Vaccine" award recognized Inovio's DNA vaccine designed to treat HPV-caused cervical dysplasia, VGX-3100. In human studies this therapeutic vaccine has demonstrated that it not only drives robust immune responses to antigens from high risk types of human papillomavirus (HPV) infection but that these immune responses display a powerful killing effect against cells changed by HPV into precancerous dysplasias. This desirable effect may ultimately contribute to the regression or elimination of cervical dysplasia, cervical cancer, and other cancers caused by HPV. These data have been published in the peer-reviewed journal, Science-Translational Medicine. Inovio is currently assessing the ability of its DNA-based VGX-3100 to treat cervical dysplasias caused by HPV infection in a global phase II trial, with results expected in the first quarter of 2014.

    The "Best Early Stage Biotech" award highlights Inovio's pioneering advancement of its proprietary SynCon® DNA vaccine and electroporation delivery technologies. Its expanding product pipeline includes clinical programs for HPV-caused dysplasia and cancers, influenza, and HIV, and preclinical programs for hepatitis C virus, hepatitis B virus, prostate cancer, malaria, and other challenging chronic infectious diseases. With its goal of "revolutionizing vaccines," Inovio is a leader in advancing the technology of synthetic DNA vaccines; it has achieved best-in-class T-cell responses, which are considered vital to treating cancers and infectious diseases, with its cervical dysplasia and HIV vaccines; and it has achieved the first human data showing the potential of a next-generation vaccine to provide protective immune responses against multiple strains of a virus that are not specifically matched to the DNA sequences represented in the vaccine.

    Dr. J. Joseph Kim, President and CEO, said, "We greatly appreciate the World Vaccine Congress' recognition of Inovio's leadership and innovation in advancing what we hope and expect to become a vital new generation of immune-system-stimulating technology: DNA vaccines. We also appreciate the specific acknowledgement of the accomplishments of VGX-3100 and its potential to become an important new approach for treating diseases caused by HPV. We look forward to the next stages of this exciting journey to revolutionize vaccines."

    About the ViE Awards
    The World Vaccine Congress & Expo, now in its 13th year, is the largest and most comprehensive event in the industry. Covering everything from the latest R&D to manufacturing to corporate development strategies, the Congress hosts the only awards ceremony dedicated to the vaccine industry. The ViE Awards honor individuals, organizations and initiatives which have made significant contributions over the past 12 months to innovation in the field of vaccines.
    Apr 18, 2013. 07:50 AM | 1 Like Like |Link to Comment
  • 3 Microcap Biopharma Plays For The H7N9 Influenza Outbreak [View article]
    Or good karma by investing in possible prevention and cures so no further deaths happen? Depends how you look at it
    Apr 17, 2013. 10:17 AM | 1 Like Like |Link to Comment
  • 3 Microcap Biopharma Plays For The H7N9 Influenza Outbreak [View article]
    While this news release is not out on INO's website yet, the link in this article is to the news release from VGX international, which is a subsidiary of INO.
    Apr 16, 2013. 04:18 PM | 1 Like Like |Link to Comment
  • Minimizing Risk When Investing In Biopharmas [View article]
    Thank you very much for the kind words everyone, I'm glad I could contribute something helpful!
    Apr 12, 2013. 11:36 AM | 1 Like Like |Link to Comment
  • Exact Sciences: A Cancer Diagnostic Play With An Upcoming Catalyst This Month [View article]
    You appear to be in a good position if there isn't good news from these upcoming results. In the event that this happens I expect it to pull back to $7.50-8.00, and you'll still be able to exit with a mild profit.

    On the flip side, if you are feeling good about the upcoming results, it wouldn't be a bad idea to pick up more at the current price, or the next small dip, and average up your overall cost-basis!
    Apr 8, 2013. 11:07 PM | Likes Like |Link to Comment
  • Oncolytics: A Failing Biopharma, Or An Opportune Buy? [View article]
    Excellent post, thank you for your input!
    My intention was to have a bipartisan bear vs bull hook in the title to bring in the people who are on either side of the issue.

    On the topic of it being modified: In the research on Reolysin, Oncolytics has referred to it being 'developed from a reovirus', leading me to believe it was in some way, shape, or form modified.
    Apr 8, 2013. 11:01 AM | Likes Like |Link to Comment
  • Biotechs Ramping Up On China's Avian Flu Outbreak [View article]
    Interesting that you didn't talk about Inovios DNA influenza vaccines. They are more universal across strains than your typical live or attenuated vaccine, and just showed a 100% gain in efficacy in the elderly during a clinical trial.

    Syncon, a universal vaccines for influenza stains is a major development as current vaccinations can only target single strains. It has successfully targeted 6 unmatched H5N1 strains tested, and 9 unmatched H1N1 strains tested

    Significant development for the elderly population, who are those most at risk for flu deaths. Has shown to increase generation of infection preventing antibodies by 100%.

    This is where my moneys at!
    Apr 8, 2013. 04:10 AM | Likes Like |Link to Comment